Rheumatoid Arthritis

Arthur Kavanaugh, MD, provides a year in review, including new developments, in rheumatoid arthritis as well as his thoughts on the use of biosimilars.

Fatigue is commonly experienced by patients with rheumatoid arthritis, so how should patients experiencing it be managed? Take this quiz on managing fatigue in rheumatoid arthritis to test your knowledge.

“Food insecurity may increase an individual’s dependence on inexpensive energy-dense foods that lead to the development of chronic diseases that may affect mental health," investigators stated.

Upadacitinib monotherapy was effective in inhibiting structural joint damage progression in patients with rheumatoid arthritis who were MTX-naïve or had an inadequate response to MTX.

Some patients with rheumatoid arthritis will complain of fatigue, but do you know which patients are most at risk? Take this quiz on the risk factors for fatigue to find out.

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending February 4, 2021.

While subclinical synovitis is a common problem in the prognosis of RA, it is difficult to detect it by imaging methods and leads to joint destruction in some patients.

Less than 5% of patients with IBD treated with azathioprine had white blood count, eGFR, ALT, and neutrophil abnormalities.

The FDA was prompted to require a safety trial comparing tofacitinib with TNF inhibitors in patients with rheumatoid arthritis.

"Prevention of severe radiographic progression in a certain percentage of patients remains a challenge because of inadequate treatment response or adverse events associated with therapeutic agents," investigators stated.

Farzin Khosrow-Khavar, MSc, PhD, discusses his study “Tofacitinib and risk of cardiovascular outcomes: results from the Safety of TofAcitinib in Routine care patients with Rheumatoid Arthritis (STAR-RA) study.”

Physical activity is known to improve function, quality of life, and pain in rheumatoid arthritis. How has the pandemic affected patients’ participation in physical activity? Test your knowledge with this quiz.

While the goal of rheumatoid arthritis treatment is low disease activity and remission, many patients are apprehensive about changing or escalating RA treatment.

For patients with rheumatoid arthritis, reduced levels of PA may impact disease activity, increase the likelihood of obesity, and may even lead to more frequent hospitalizations.

Analysis of self-reported wellness and health may provide insight into an overall subjective picture of wellbeing and health status. Mood, sleep quality, and sleep quantity were shown to impact these scores.

Early diagnosis and prompt effective management are important for the best outcomes in rheumatoid arthritis. Test your knowledge of how to achieve this with this quiz.

While patients with rheumatoid arthritis on rituximab therapy have been reported to have insufficient serological responses to the COVID-19 vaccine, T cells, which protect against severe COVID-19, may be elevated after a third dose.

While patients with rheumatoid arthritis may benefit from either increasing or decreasing their dosage of tofacitinib, post-hoc analysis indicates that safety and efficacy of the medication is not impacted by these changes.

An increased frequency of serious infections and antimicrobial prescriptions was seen in patients with rheumatoid arthritis currently being treated with a TNFi.

Treatment for rheumatoid arthritis has been associated with the development and worsening of some lung conditions. Test your knowledge with this quiz.

Patients with rheumatoid arthritis often have lung conditions. How much do you know about the risks of lung disease associated with rheumatoid arthritis? Test your knowledge with this quiz.

Cannabidiol (CBD) may be used separately or in conjunction with standard treatment to reduce symptoms of juvenile idiopathic arthritis.

Test your knowledge of the treatment and management of rheumatoid arthritis with our latest RA quizzes.

Roy Fleischmann, MD, explores the successful results of the novel IL-6 inhibitor, olokizumab, from 2 randomized clinical trials of the phase 3 global research program CREDO.

Selective Janus kinase (JAK) inhibitor, upadacitinib, is now intended for adults with moderate-to-severe rheumatoid arthritis (RA) who have had inadequate response or intolerance to at least 1 tumor necrosis factor (TNF) blocker.